Investors: Capture New, Unaddressed Market Opportunities
60° Pharmaceuticals (60P): A two-pronged mission for investors
Investing in an established market
A tremendous investment opportunity exists due to the ineffective preventative malaria therapies currently on the market along with expanding disease risks. This calls for more effective and efficient prevention therapies.
60P: Exclusive rights to develop Tafenoquine (for malaria prevention)
Competitive advantages in dengue fever treatment
The experience to succeed
Founded by industry veterans, 60P has leadership with over 80 years of combined pharmaceutical business experience—including new product development, product management, regulatory approval, and marketing.
60P Collaboration Partners
60P Distribution Partners
Innovation and product development
To innovate new tropical disease treatments, 60P collaborates with other public and private entities to proceed collectively.
A partnership built on trust and efficiency
As 60P continues to achieve significant clinical development milestones, the expansion arising out of investment will enable 60P to accelerate its path to market. Ideally, 60P seeks to augment its experience in development, manufacturing, and commercialization of drugs.
Headquarters: Washington, D.C. (USA)
Research and Development: Australia
FORWARD LOOKING STATEMENTS: This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, our financial guidance, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “targets,” “forecasts,” “estimates” and similar expressions in conjunction with, among other things obtaining future product sales, discussions of the Company’s outlook, financial performance or financial condition, growth strategy, government development or procurement contracts or awards, government appropriations, manufacturing capabilities, product development, or regulatory approvals or expenditures and plans to increase our operational efficiencies and cost structure are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.